REGN
Is Regeneron Pharmaceuticals's (REGN) dividend safe?
Regeneron Pharmaceuticals (REGN) currently pays a dividend yield of 0.5% with an FCF payout ratio of 8.5%. Dividend safety isn't about the yield (high yields often signal stress) it's about whether free cash flow comfortably covers the payment. The full coverage analysis is below. Educational only, not investment advice.
FCF payout coverage. Regeneron Pharmaceuticals's free-cash-flow payout ratio is n/a. Below 60% is comfortable: the business is keeping at least 40% of cash for reinvestment, debt reduction, or buybacks. Between 60-90% is workable but tighter; above 90% leaves no buffer, which is where dividend cuts become a real risk during a downturn.
Earnings vs FCF. The traditional payout ratio (dividends / earnings) sits at 8.5%. Compared against the FCF payout ratio above, large gaps indicate one of two things: accounting earnings being inflated by non-cash items (FCF payout much higher than earnings payout, red flag) or aggressive cash management lifting near-term FCF (FCF payout much lower than earnings payout, sometimes a sign of working-capital releases that won't repeat).
Growth track record. Regeneron Pharmaceuticals's 5-year dividend CAGR is n/a. Consistent growth across at least one downturn is the gold standard: it means management treats the dividend as a commitment, not a discretionary outflow. A 5-year track record without a cut during the last recession is much stronger evidence than a high current yield.
How invest-like measures this
Dividend safety isn't about the yield: a high yield often signals stress. It's about coverage: does free cash flow comfortably cover the dividend with room to spare? The invest-like dividend-safety score weighs three signals: FCF payout ratio (under 60% is comfortable; over 90% is fragile), earnings payout ratio (less reliable than FCF because accruals can mask cash shortfalls), and dividend growth track record (consistent 5-year CAGR vs cuts during the last downturn).
Educational only: even an A-rated dividend can be cut tomorrow by a single board decision. We're measuring documented financial capacity to maintain the payout, not predicting management intent.
This is educational analysis based on investing frameworks. It is not investment advice or a recommendation, and it does not know your situation. Do your own research before you decide.
